STRen Italian follow-up network for islet-autoantibody-positive people
What this study tests
Prospective Italian network designed to follow children and adults found with at least one islet autoantibody for up to ten years, tracking progression to stage-3 T1D and DKA at diagnosis. It is follow-up after screening, not itself a national screening service.
Editorial review: .
Registry checked: 2026-09-17. Registry’s own update: 2026-04-08.
Most recent recorded citation date: 2026-04-08. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence at a glance
- Who can enter the study?
- People of any age with at least one islet autoantibody, no diabetes symptoms, and no glucose or HbA1c result meeting diagnostic criteria for diabetes; see the registry for full criteria. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- No results posted. The registry still listed NOT_YET_RECRUITING on 8 August 2026, although its estimated May 2026 start had passed. Estimated enrollment is 300 and completion is April 2036. The passed estimate is not evidence that enrollment began or that the programme is delayed.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: European Union. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability.
Primary endpoints
- Progression to stage-3 T1D over up to ten years
The full picture
This record has no longer discussion. Use the study criteria, reported results and original sources on this page to assess what is known and what remains unresolved.
Sources
- [1]NCT07503366: Standardized Italian Network Enrolling Individuals With Islet Autoantibodies (STRen) · Trial registry · 2026-04-08 — NOT_YET_RECRUITING; estimated n=300; 24 Italian locations listed; estimated start May 2026 and completion April 2036.